Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:CNST OTCMKTS:INVVY NASDAQ:PHAT NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$14.48-2.1%$12.58$8.04▼$25.88$392.70M2.27419,691 shs415,308 shsCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/AINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsPHATPhathom Pharmaceuticals$9.69+3.4%$6.53$2.21▼$19.71$676.50M0.451.55 million shs619,638 shsRYTMRhythm Pharmaceuticals$89.04+0.0%$63.38$40.61▼$94.58$5.66B2.26585,646 shs2.54 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+7.17%+8.59%+17.94%+58.18%-34.21%CNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INVVYIndivior0.00%0.00%0.00%0.00%0.00%PHATPhathom Pharmaceuticals+3.88%+5.16%+6.12%+127.98%-10.85%RYTMRhythm Pharmaceuticals+36.63%+32.99%+33.39%+53.90%+98.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics2.6893 of 5 stars3.62.00.00.01.92.50.6CNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/APHATPhathom Pharmaceuticals3.3468 of 5 stars4.51.00.00.00.05.00.6RYTMRhythm Pharmaceuticals3.5144 of 5 stars2.52.00.04.32.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.11Buy$54.00272.93% UpsideCNSTConstellation Pharmaceuticals 0.00N/AN/AN/AINVVYIndivior 0.00N/AN/AN/APHATPhathom Pharmaceuticals 3.00Buy$17.5080.60% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$89.360.36% UpsideCurrent Analyst Ratings BreakdownLatest INVVY, PHAT, ARCT, RYTM, and CNST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/10/2025RYTMRhythm PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$76.00 ➝ $110.007/10/2025RYTMRhythm PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $95.007/10/2025RYTMRhythm PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$91.00 ➝ $129.007/10/2025RYTMRhythm PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$97.007/9/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$72.00 ➝ $95.007/7/2025RYTMRhythm PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025RYTMRhythm PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$88.007/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.006/26/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$84.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$152.31M2.58N/AN/A$8.90 per share1.63CNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/AINVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07PHATPhathom Pharmaceuticals$81.86M8.26N/AN/A($3.71) per share-2.61RYTMRhythm Pharmaceuticals$130.13M43.53N/AN/A$0.35 per share254.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)CNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/AINVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/APHATPhathom Pharmaceuticals-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/6/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$2.81N/AN/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)Latest INVVY, PHAT, ARCT, RYTM, and CNST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.64N/AN/AN/A$43.72 millionN/A8/4/2025Q2 2025ARCTArcturus Therapeutics-$1.11N/AN/AN/A$17.64 millionN/A5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ACNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus Therapeutics0.065.645.64CNSTConstellation PharmaceuticalsN/A15.3915.39INVVYIndiviorN/AN/AN/APHATPhathom PharmaceuticalsN/A3.583.54RYTMRhythm PharmaceuticalsN/A3.303.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%CNSTConstellation PharmaceuticalsN/AINVVYIndivior0.05%PHATPhathom Pharmaceuticals99.01%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics16.60%CNSTConstellation Pharmaceuticals43.70%INVVYIndiviorN/APHATPhathom Pharmaceuticals23.00%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.12 million22.62 millionOptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableINVVYIndivior800137.88 millionN/ANot OptionablePHATPhathom Pharmaceuticals11069.81 million53.76 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million59.74 millionOptionableINVVY, PHAT, ARCT, RYTM, and CNST HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals (NASDAQ:RYTM) Given New $110.00 Price Target at OppenheimerJuly 10 at 2:36 PM | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given New $95.00 Price Target at Bank of AmericaJuly 10 at 12:11 PM | marketbeat.comRYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study DataJuly 10 at 12:11 PM | zacks.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysJuly 10 at 11:13 AM | marketbeat.comRhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar?July 10 at 11:05 AM | zacks.comRhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common StockJuly 10 at 10:22 AM | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Earns Buy Rating from Analysts at The Goldman Sachs GroupJuly 10 at 9:12 AM | marketbeat.comRhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common StockJuly 10 at 8:21 AM | gurufocus.comAnalysts Issue Forecasts for RYTM Q2 EarningsJuly 10 at 8:17 AM | marketbeat.comRhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock | ...July 10 at 6:57 AM | gurufocus.comRhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common StockJuly 10 at 6:21 AM | globenewswire.comRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo ...July 10 at 5:15 AM | finanznachrichten.deBrokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $77.31July 10 at 2:39 AM | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 12-Month High After Analyst UpgradeJuly 10 at 2:38 AM | marketbeat.comRhythm Pharma Shares Gain on Positive Results From Recent Trial of Obesity TreatmentJuly 9 at 12:14 AM | marketwatch.comRhythm's drug shows promise in study to treat brain damage-related obesityJuly 9 at 12:14 AM | reuters.comRhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity - MorningstarJuly 9 at 12:14 AM | morningstar.comMPositive trial results for Rhythm Pharma oral MC4R agonist bivamelagonJuly 9 at 12:14 AM | thepharmaletter.comTRhythm’s phase 2 obesity pill trial hits primary endpoint, sending stock upJuly 9 at 12:14 AM | fiercebiotech.comFRhythm Stock: Obesity Drug Spurs Analyst OptimismJuly 9 at 12:14 AM | sharewise.comSRhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity DrugJuly 9 at 12:14 AM | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINVVY, PHAT, ARCT, RYTM, and CNST Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$14.48 -0.31 (-2.10%) Closing price 04:00 PM EasternExtended Trading$14.44 -0.04 (-0.24%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Constellation Pharmaceuticals NASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Indivior OTCMKTS:INVVY$21.85 -0.40 (-1.82%) As of 06/9/2023Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Phathom Pharmaceuticals NASDAQ:PHAT$9.69 +0.32 (+3.42%) Closing price 04:00 PM EasternExtended Trading$9.52 -0.17 (-1.75%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$89.04 +0.04 (+0.04%) Closing price 04:00 PM EasternExtended Trading$88.36 -0.68 (-0.76%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
